Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT05705986 |
Other study ID # |
20D.098 |
Secondary ID |
|
Status |
Recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
February 26, 2021 |
Est. completion date |
May 2024 |
Study information
Verified date |
January 2023 |
Source |
Thomas Jefferson University |
Contact |
Silva Markovic-Plese, MD, PhD |
Phone |
215-503-6393 |
Email |
Silva.Markovic-Plese[@]jefferson.edu |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Microparticles (MPs) as a mode of therapeutic delivery can selectively deliver
immunomodulatory treatment to the phagocytic cells, particularly dendritic cells (DCs),
inducing their tolerogenic phenotype and function and T regulatory (Treg) cell expansion. The
study will characterize the in vitro response of cGAMP immunomodulator incapsulated
microparticles on the capacity of DCs and Tregs to regulate the inflammatory response.
Description:
This is a lab study only. No medication will be dispensed as a part of the study. No tests or
procedures will be performed. Blood ( approximately 10 teaspoons ; 10 green top tubes) will
be drawn by a qualified phlebotomist, nurse or physician in the Neurology clinic, during
routine clinic visits. Proper medical procedures will be followed when collecting blood to
minimize patient risk. In addition, steps will be taken to guard patient's confidentiality.
Unique codes will be assigned to each sample. All identifying information will be removed
from samples and clinical data before they are given to the research staff conducting the
laboratory study. Only the clinic staff will have access to the consent forms, the master
list (that connect the unique codes with the patient names) and subject medical records. The
blood draw will coincide with the subject's regular visit to the Neurology clinic.
All records will be secured with the current PACS radiology system and computerized
information systems/computerized databases which are the current methods for securing all
patient information. Care will be taken to preserve the confidentiality of all
patient-related information. Material with identifying information will be stored in the
clinic locked data storage room. Patient names will not be used in any publications. Results
of laboratory studies performed on these samples will not be shared with subjects. Laboratory
results will not be incorporated into patients medical records.
The proposal states to separate dendritic cells using magnetic beads separation and use them
as an antigen presenting cells to T cells.The therapeutic effect of the nanoparticle
delivered phosphatidylserine (PS, PAR-PS) will be measured, using cytokine secretion and the
detection of the T regulatory (Treg) cell induction. Proliferation will be determined using
CFSE, cytokine secretion will be measured using ELISA and the intracellular cytokine staining
for IFNg, IL-17A, IL-17F, IL-21, IL-22, TGFb, IL-10 and IL-4. The induction of Treg cells
will be measured using flow cytometry and determining the percentage of CD4+ CD25+ CD127-
FoxP3+ Treg cells within the CD4+ lymphocytes.